oligodendrocytes

A cell therapy product derived from human umbilical cord blood cells may be a promising treatment approach for patients with demyelinating diseases, such as multiple sclerosis (MS) or leukodystrophy, according to a recent study developed at the Duke University Medical Center. The study, “A cord blood monocyte–derived cell…

A research project that aims to explore how astrocytes can be manipulated to stop or prevent neurodegeneration has received a grant from the National Stem Cell Foundation (NSCF). The project will be conducted by the The New York Stem Cell Foundation (NYSCF) Research Institute. The work developed by Dr. Valentina…

Endece was recently issued an additional U.S. patent for its lead investigational product, NDC-1308, being developed to induce remyelination in patients with multiple sclerosis (MS) and prevent disease progression. Currently in late preclinical development, NDC-1308 is designed to repair the myelin sheath of demyelinated axons (nerve fibers), a major cause…

A substance called fluorosamine was seen to boost remyelination in mice by preventing the synthesis of chondroitin sulfate proteoglycans and by promoting oligodendrocyte function. The findings showed that targeting molecules that block remyelination may be a promising therapeutic approach in multiple sclerosis (MS). Upregulation of chondroitin sulfate proteoglycans — large molecules…

RegeneRx Biopharmaceuticals, Inc., announced the publication of a research article detailing the process by which Thymosin beta 4 (Tβ4), the company’s novel therapeutic peptide, effectively promoted the remyelination process in two separate animal models commonly used for multiple sclerosis (MS) research. The article, “Thymosin beta4 promotes oligodendrogenesis in the demyelinating…

Premature infants are known to be at risk of cerebral injury due to oxygen deprivation and later problems with cognitive development, but an immunomodulating drug mostly used in the treatment of multiple sclerosis (MS) may be of help. Researchers in Germany and Switzerland reported that the drug fingolimod (Gilenya) prevented brain…

Novoron Bioscience, Inc., a biotech company focused on developing therapies for disorders of the central nervous system, recently announced that it has received a $680,000 National Institutes of Health (NIH) grant to assess the potential of a new therapeutic approach to induce remyelination in multiple sclerosis (MS). MS is…

Researchers are proposing for a first time that multiple sclerosis (MS) is triggered by the death of a specific cell population within the central nervous system called oligodendrocytes. The study, titled “Oligodendrocyte death results in immune-mediated CNS demyelination,” was published in the journal Nature Neuroscience. Oligodendrocytes,…

A new study in the Journal of Cell Biology suggests that vitamin D activates a receptor involved in myelin regeneration in patients with multiple sclerosis (MS). The study, entitled “Vitamin D receptor–retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation,” and was led by researchers…

The Fifth Tykeson Fellows Conference brought senior multiple sclerosis (MS) scientists together with nearly 100 young research and clinical fellows from the National Multiple Sclerosis Society, MS Society of Canada, and MS International Federation to promote collaboration, networking, and the sharing of research data with the goal of improving patients’ lives and developing…

In a new study, researchers have revealed the previously unknown function of the FAM126A gene in supporting myelination (the formation of the myelin sheath that protects neurons), a critically important process in the development and recovery of acute exacerbations in multiple sclerosis (MS). The research paper, entitled “The leukodystrophy protein…

The Multiple Sclerosis Society (MS Society) in the United Kingdom recently announced the investment of £1.98 million in new MS research. After an in-depth, rigorous review process of the 58 applications submitted, 16 projects were awarded funding through the MS Society’s 2015 grant round totaling £1,979,879. All applications…

In a recent study entitled “Promotion of Remyelination by Sulfasalazine in a Transgenic Zebrafish Model of Demyelination,” researchers investigated whether sulfasalazine treatment, an anti-inflammatory and immune-modulating drug, could promote remyelination of axons in an organism model of demyelination diseases such as multiple sclerosis (MS). The study was published in the…

Alexander Gow, Ph.D., a professor at the Wayne State University School of Medicine, has just been awarded a research grant by the National Multiple Sclerosis Society to fund his exploration of a novel model of MS pathology. Gow is a holder of the Charles H. Gershenson Distinguished Fellow Professor…

A new study recently published in the journal Nature Communications led by researchers at The University of Chicago revealed that a drug for hypertension has a protective effect against symptoms characteristic of multiple sclerosis (MS) in mouse models. The study is entitled “Pharmaceutical integrated…